Month: February 2021

MIRAMAR, Fla., Feb. 10, 2021 (GLOBE NEWSWIRE) — Spirit Airlines, Inc. (NYSE: SAVE) today reported fourth quarter and full year 2020 financial results.Ended the year 2020 with $1.9 billion of unrestricted cash, cash equivalentsand short-term investment securities“Soft demand driven by pandemic-related concerns continues to have a significant impact on our operating results. However, our leading low-cost structure remains a key advantage and positions us well to compete in this environment and beyond. Our load factor and Adjusted EBITDA margin for the fourth quarter 2020 are among the best in the industry, illustrating the strength of our business model,” said Ted Christie, Spirit’s President and Chief Executive Officer. “While the road to recovery is anticipated to be choppy, we are confident we will be among the first U.S. carriers...

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it plans to make a public offering of 3,000,000 shares of its common stock, par value $0.0001 per share, in an underwritten registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to 450,000 additional shares of its common stock.The Company intends to use the net proceeds from this offering, together with its existing cash, to advance clinical and preclinical development of its product candidates, prepare for commercialization and other general corporate purposes.Goldman Sachs & Co. LLC, Cowen...

CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — Birchcliff Energy Ltd. (“Birchcliff” or the “Corporation”) (TSX: BIR) is pleased to announce its unaudited 2020 year-end and fourth quarter financial and operational results and highlights from its independent reserves evaluation effective December 31, 2020.Jeff Tonken, President and Chief Executive Officer of Birchcliff commented: “Birchcliff is proud to announce its fourth quarter and full-year 2020 results. 2020 was a challenging year for Birchcliff and for the industry as a whole. Despite the economic damage and pricing uncertainty caused by the COVID-19 pandemic, we were able to efficiently execute our 2020 capital program, generating annual adjusted funds flow of $185 million, with annual average production of 76,401 boe/d and record low annual operating costs of $2.95 per/boe....

HOUSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) — Amplify Energy Corp. (NYSE: AMPY) (“Amplify” or the “Company”) announced today the appointment of Patrice Douglas to the Company’s Board of Directors (the “Board”). Ms. Douglas will serve on the Audit Committee of the Board.Ms. Douglas is an attorney, who represents financial institutions, energy companies, municipalities, and utilities on legal, regulatory and compliance matters. Previously, Ms. Douglas served as Senior Vice President and then President of SpiritBank from 2004 to 2007 and Executive Vice President of First Fidelity Bank from 2007 to 2011. Ms. Douglas was elected as mayor of Edmond, Oklahoma in 2009 and served for two terms. As a member of the U.S. Conference of Mayors, she served on the committee for tourism. Ms. Douglas was appointed by Oklahoma’s Governor to the Oklahoma...

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020.Recent Business HighlightsPhase 2b study of RZ358 continues to enroll congenital hyperinsulinism (HI) patients worldwide – The RIZE Phase 2b study of RZ358 for the treatment of congenital HI continues to enroll patients, with study completion expected in the second half of 2021. RZ358 is an allosteric modulator of the insulin receptor being developed as a treatment for all forms of congenital HI.Initiation of Phase 1 study of RZ402 – In January 2021, Rezolute announced initiation of dosing in a Phase 1 clinical study of oral plasma kallikrein inhibitor RZ402 in healthy volunteers. RZ402 is a potential first-in-class therapy being investigated as a once-daily oral treatment...